Introducing 

Prezi AI.

Your new presentation assistant.

Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.

Loading…
Transcript

5.1.3 Grant Proposal

Ulysses Andrade,

Jasmine Nguyen,

Izabel Torres

December 18, 2019

A PATH TO A CURE

Company Background

  • Biomedical Innovations
  • 1st Period
  • Wednesday December 18, 2019
  • 9:05 Presentation

Company Intro

Our Team

Our Team

Leaders of Acute Myeloid Leukemia Research

Jasmine Nguyen

Izabel Torres

Ulysses Andrade

Our Clients

Our Clients

All Children and Adults Affected with Acute Myeloid Leukemia (AML)

The Brief

Acute Myeloid Leukemia is a very aggressive and progressive form of leukemia diagnosed in adults and young children.

The Brief

Objectives

1.

: Increase survival rates within patients who are diagnosed with AML

Objectives

2.

Lower diagnosis numbers in patients with a form of leukemia

3.

Increase survival rate from treatment for AML

OBJECTIVE 1:

  • Patients under the age of 20 has the survival rate of 67%
  • Over the age of 20 survival rate drops to 24%.
  • By incorporating targeted therapy into clinical trials:

-patients will have specific enzymes, proteins and molecules that assist tumor tissue in its production.

OBJECTIVE 2:

  • AML is the second most rare case of leukemia
  • Makes up about 32% of adult cases of leukemia
  • Could be caused by radiation and chemotherapy
  • By improving targeted therapy, a less invasive treatment, the risk of getting AML will decrease significantly.

OBJECTIVE 3:

  • 38.6% of patients with leukemia die.
  • Currently, the most “effective” treatment option is intensive chemotherapy, chemotherapy with phases, and radiation
  • Chemo and radiation, weakens the patient’s body
  • targeted therapy will block the growth and spread of leukemia cells

Agenda

Agenda

By receiving the proper funding, research on improving targeted therapy could surpass chemotherapy and radiation therapy. The more research found on targeted therapy:

  • the less side effects it will have
  • recognized as a suitable source of treatment to all patients with a form of leukemia all across the nation.

Executive summary

Solution

Problem:

Projected Result

Executive summary

Goal is to be able to utilize the research gained from targeted therapy to apply it as an acceptable form of treatment for patients with AML

If government funding can aid in the creation of educational clinics and promising clinical trials, then children and adults would become more aware of the warning signs and treatment through clinical trials, specifically through “Targeted Therapy”.

Acute Myeloid Leukemia is a rare form of cancer of the blood in which there are too many immature white blood cells being produced from the bone marrow.

Strategy

  • 3 Key Steps to Ensure Fulfillment of Grant

Strategy

Deliverable 1

1. Before the initial project takes off, the first priority of the clinical trial will be to find the appropriate pool of subjects.

Deliverable 1

2. The criteria will be

  • patients diagnosed with AML
  • patients whose AML was developed genetically,
  • patients who developed AML through some form of treatment
  • patients who are at the beginning stages of AML
  • ( no more than 20 patients )

Deliverable 2

1. Hematologist-oncologist will be responsible for finding patients who are suitable for this research

Deliverable 2

2. A consensual NDA form, that will prevent any research from leaving the facility and in case of a lawsuit that a subject may bring up in the future

3. These preparations are meant to take no longer than 2 months.

Deliverable 3

1. The first three months of trial will be used to find the appropriate dosage per subject.

-General Physicians and Dieticians

Deliverable 3

2. Once the proper dosages are implemented, the patients are to receive targeted therapy daily.

-Hematologist-Oncologist

3. As the clinical trial continues, the medication and treatment will be further more developed where it will be less rigorous and invasive

Next steps

-The bi-weekly reports that were taken within the span of the trial will show that the excess of immature white blood cells have lowered significantly--

Next steps

Timeline

Stage 1

-finding 20 patients

-NDA Forms

Stage 2

-educational consultation

-blood withdraws

-pretreatment

Stage 3

-The next three months of trial will be used to find the appropriate dosage per subject.

Timeline

Time

Sources:

Sources

  • YouTube. (n.d.). Retrieved from https://www.youtube.com/watch?v=j0ruBn1XM24
  • Acute Myeloid Leukemia. (n.d.). Retrieved from https://www.lls.org/leukemia/acute-myeloid-leukemia?src1=20032&src2=
  • Who's Who on Your Healthcare Team. (n.d.). Retrieved from https://www.lls.org/managing-your-cancer/communicating-with-your-specialist/whos-who-on-your-healthcare-team
  • Acute Myelogenous Leukemia Facts. (n.d.). Retrieved from https://www.seattlecca.org/diseases/acute-myelogenous-leukemia-aml/aml-facts
  • Acute Myeloid Leukemia. (n.d.). Retrieved from https://www.cityofhope.org/clinical-program/acute-myeloid-leukemia?gclid=CjwKCAiAis3vBRBdEiwAHXB29CY3wga7qllCALG7AxH_Uy9nySSRQvjHz0ay7wNd_tkR
Learn more about creating dynamic, engaging presentations with Prezi